NEC Baby Formula

● CAMPAIGN OPEN BELLWETHER TRIALS 4 signals
NEC — Necrotizing Enterocolitis (premature infants)  ·  Cow’s-Milk-Based Preterm Formula
DEFENDANT
Abbott (Similac) / Mead Johnson (Enfamil)
MDL / DOCKET
MDL 3026
N.D. Illinois
JUDGE
Hon. Rebecca Pallmeyer
PLAINTIFFS
1,000+
BELLWETHER / TRIAL
First bellwether 2024–2025
SETTLEMENT STATUS
None — active trials
📋 Case Overview

NEC (Necrotizing Enterocolitis) is a devastating gastrointestinal disease primarily affecting premature infants. Studies show cow’s-milk-based preterm formula significantly increases NEC risk compared to human donor milk. Abbott (Similac) and Mead Johnson (Enfamil) are alleged to have marketed their cow’s-milk formulas for premature infants despite knowing the NEC risk, while suppressing research supporting donor human milk.

⚗ CAUSATION SUMMARY

Multiple randomized controlled trials and meta-analyses show cow’s-milk-based formula increases NEC risk in premature infants vs. human donor milk. The mechanism involves disruption of the premature intestinal microbiome. AAP guidelines recommend donor human milk for preterm infants. Defendants are alleged to have been aware of these studies and failed to warn NICUs.

⚖️ Litigation Status GROWING
MDL / Court
MDL 3026 — Active (N.D. Ill., Judge Pallmeyer)
Active Plaintiffs
1,000+

Bellwether trials are underway in both federal MDL and Illinois state court. Abbott and Mead Johnson are contesting causation aggressively. Illinois state court has produced the largest early verdict. No global settlement negotiations have been reported.

Key Verdicts & Settlements
⚖️
Illinois state verdict — $495M vs. Abbott (2022)
First major verdict in NEC litigation. Established jury receptiveness to failure-to-warn theory.
⚖️
Federal bellwether trials ongoing (2024–2025)
Mixed results. Defendants contesting general causation. Each trial outcome affects settlement posture.
📋
No global settlement — defendants fighting
Abbott and Mead Johnson have not opened settlement discussions. Resolution timeline is 2026–2028.
📈
Filing trend: Growing. NICU records are the key qualifying document. Campaign window is open. First federal bellwether results will drive case valuations and settlement discussions.
📍 Geographic Exposure
Nationwide — NICUs in all states
No geographic restriction
Claims arise from NICU admissions nationwide
🏢 Key Defendants
DEFENDANT
ROLE
INTEL NOTE
Abbott Laboratories (Similac)
Primary manufacturer
Similac Special Care preterm formula; major defendant
Mead Johnson Nutrition (Enfamil)
Primary manufacturer
Enfamil Premature formula; co-primary defendant
✅ Campaign Eligibility Criteria
Premature infant (born before 37 weeks gestation)
Fed exclusively or primarily cow’s-milk-based preterm formula (Similac or Enfamil brands)
Diagnosed with NEC (confirmed by surgeon or radiologist)
NEC resulted in surgery, permanent injury, or death
Within 2 years of injury/death date
These criteria reflect general case strength indicators and are not legal advice. Contact CloudIntake to screen individual claimants.
📅 Litigation Timeline
1990s
Research begins showing elevated NEC risk with cow’s-milk formula vs. human milk in preemies
2012
AAP issues guidance recommending pasteurized donor human milk for preterm infants
2022
First major verdicts: $495M (Abbott) in Illinois state court
2022
MDL 3026 formed in N.D. Illinois
2024
Bellwether trials underway; mixed plaintiff/defense results
2025
Additional bellwether trials scheduled; no global settlement yet
NEC Baby Formula — Intelligence Feed LIVE
📰 NEWS
NEC lawsuits grow as more families pursue Similac and Enfamil baby formula claims
Mar 13, 2026 Class Action Lawsuits Read Source →
📰 NEWS
NEC Baby Formula Lawsuit & Settlement | March 2026 Update
Mar 13, 2026 Lawsuit Information Center Read Source →
📰 NEWS
Trial begins over claims Abbott baby formula caused bowel disease
Mar 13, 2026 The Cattle Site Read Source →
📰 NEWS
Trial Set in NEC Multidistrict Litigation Against Reckitt Benckiser’s Mead Johnson Led by Levin Papantonio
Mar 13, 2026 Yahoo Finance Read Source →
Feed All Torts
MASS TORT AD AGENCY
High CPLs are a creative problem.
When every firm runs the same ad, CPLs spike. MTAA’s NEC Baby Formula creative is engineered to stand out and bring costs back down.
Fix Your CPL →
Plaintiff attorneys only · mtaa.ai
JACOB SCORE™
NEC Baby Formula
70 / 100
ScienceStrong
MomentumModerate
CampaignModerate
TimelineModerate
VerdictsModerate
PLAINTIFF VERDICTS · ACTIVE MDL
Jacob Score™ — Methodology & Legal Disclaimers
The Jacob Score is a composite 1–100 litigation opportunity index for mass torts, produced by the TortIntel editorial team at Mass Tort Ad Agency. It is updated periodically as litigation conditions change.

Score Dimensions (each rated 1–5)

Science — Peer-reviewed study quality and quantity, relative risk magnitude, replication across independent research groups, FDA or regulatory action taken, and estimated Daubert survivability based on published expert testimony and prior rulings.

Momentum — MDL formation and phase, plaintiff count trajectory, case consolidation activity, and overall litigation velocity.

Campaign — Current filing window status, case saturation, defendant solvency, estimated qualifying population size, and co-defendant dynamics.

Timeline — Proximity to first expected resolution or bellwether trial, current discovery or Daubert phase, and estimated time-to-value for a signed plaintiff.

Verdicts — Confirmed plaintiff jury verdicts, bellwether trial win/loss record, and size or certainty of any established settlement fund. 1 = pre-trial · 2 = mixed early results · 3 = partial settlements or initial wins · 4 = confirmed large verdicts or funded settlement · 5 = landmark verdicts with formal settlement program.

LEGAL DISCLAIMERS

The Jacob Score and all associated content on TortIntel.ai is provided solely for mass tort business intelligence and law firm marketing decision-making purposes. It does not constitute legal advice, litigation strategy advice, or a recommendation to file or refrain from filing any lawsuit.

The Jacob Score is an editorial opinion based on publicly available data including court filings, published scientific literature, regulatory actions, and reported settlement information. It is not a guarantee of future litigation outcomes. Past verdicts and settlements are not predictive of future results in any specific case.

TortIntel.ai and Mass Tort Ad Agency make no representation that any score is complete, accurate, or current. Litigation conditions change rapidly. Attorneys must conduct independent due diligence and consult qualified co-counsel before making any case acquisition or litigation funding decisions based on this or any other intelligence tool.

This score must not be used to evaluate, accept, or reject any individual plaintiff’s case. Case-specific merit depends on individual facts, applicable state law, expert medical and scientific analysis, and jurisdiction-specific statutes of limitations — all of which are beyond the scope of this tool.

No attorney-client relationship is created by use of this platform. TortIntel.ai is not a law firm and does not provide legal services. © 2026 Mass Tort Ad Agency / TortIntel.ai. All rights reserved.
DATA ACCURACY
See something incorrect? Reach out and we'll fix it.
🔔 Alert Me
Get notified when NEC Baby Formula updates.
✓ You're subscribed. We'll notify you of key developments.
TORTINTEL PRO
Abuse Discovery Tracker
Emerging institutional abuse cases — church, scouting, youth programs. Real-time defendant monitoring, filing window alerts, and filing cluster detection.
View Pro Features →